SERA Sera Prognostics, Inc. Stock Quote

SERA [NASD]

Healthcare | Diagnostics & Research | USA

Index	-	P/E	-	EPS (ttm)	-1.33	Insider Own	0.30%	Shs Outstand	30.80M	Perf Week	-1.33%
Market Cap	45.76M	Forward P/E	-	EPS next Y	-1.51	Insider Trans	-25.63%	Shs Float	21.53M	Perf Month	-33.63%
Income	-40.90M	PEG	-	EPS next Q	-0.37	Inst Own	55.10%	Short Float	1.31%	Perf Quarter	-73.33%
Sales	0.10M	P/S	457.62	EPS this Y	-76.40%	Inst Trans	2.28%	Short Ratio	3.34	Perf Half Y	-86.47%
Book/sh	4.13	P/B	0.36	EPS next Y	2.50%	ROA	-30.80%	Target Price	10.33	Perf Year	-
Cash/sh	3.48	P/C	0.43	EPS next 5Y	-	ROE	-58.40%	52W Range	1.43 - 15.50	Perf YTD	-78.46%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-90.45%	Beta	-
Dividend %	-	Quick Ratio	15.80	Sales past 5Y	-	Gross Margin	51.40%	52W Low	3.50%	ATR	0.21
Employees	115	Current Ratio	15.80	Sales Q/Q	333.30%	Oper. Margin	-	RSI (14)	24.34	Volatility	8.03% 11.55%
Optionable	No	Debt/Eq	0.01	EPS Q/Q	-90.20%	Profit Margin	-	Rel Volume	3.29	Prev Close	1.52
Shortable	Yes	LT Debt/Eq	0.01	Earnings	May 10 AMC	Payout	-	Avg Volume	84.24K	Price	1.48
Recom	1.80	SMA20	-22.50%	SMA50	-43.19%	SMA200	-79.69%	Volume	277,038	Change	-2.63%

Mar-30-22

Downgrade

Citigroup

Buy → Neutral

$18 → $4

Nov-19-21

Initiated

Oppenheimer

Outperform

$19

Oct-15-21

Resumed

Cowen

Outperform

May-19-22 04:15PM	SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE PR Newswire
May-18-22 03:03PM	SERA PROGNOSTICS PRESENTS DATA DEMONSTRATING THE HEALTH AND ECONOMIC BENEFIT OF PRETRM® TESTING AT ISPOR ANNUAL MEETING PR Newswire
May-10-22 04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS PR Newswire
May-05-22 08:30AM	SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUITY THROUGH THE "EVERY MOTHER, EVERY BABY" PROJECT PR Newswire
May-02-22 08:30AM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10 PR Newswire
Apr-12-22 08:30AM	SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD PR Newswire -11.31%
Mar-30-22 07:30AM	Sera Prognostics, Inc. (SERA) Q4 2021 Earnings Call Transcript Motley Fool -7.65%
Mar-29-22 04:00PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS PR Newswire +12.19%
Mar-18-22 12:00PM	Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting PR Newswire -14.45%
07:00AM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29 PR Newswire
Mar-03-22 08:30AM	SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES PR Newswire -6.05%
Feb-17-22 08:30AM	SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE PR Newswire
Feb-07-22 08:30AM	SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES PR Newswire
Feb-01-22 08:30AM	SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TEST PR Newswire
Dec-15-21 08:30AM	SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX PR Newswire
Dec-02-21 08:00AM	Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth PR Newswire
Dec-01-21 11:40AM	Sera Prognostics Announces Publication Of Data Confirming The Performance Of The IBP4/SHBG Biomarkers In Diverse Non-U.S. Populations PR Newswire
Nov-30-21 08:00AM	Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board PR Newswire
Nov-10-21 09:01AM	Sera Prognostics, Inc. (SERA) Q3 2021 Earnings Call Transcript Motley Fool
Nov-09-21 04:01PM	Sera Prognostics Reports Third Quarter 2021 Financial Results PR Newswire
Nov-08-21 04:20PM	Sera Prognostics Announces The Appointment Of Zhenya Lindgardt To The Board PR Newswire
Nov-04-21 08:00AM	Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs PR Newswire +5.63%
Nov-03-21 08:00AM	Sera Prognostics Announces Publication of the Clinical Validation of PreTRM® Threshold for Clinical Action PR Newswire
Nov-02-21 08:00AM	Sera Prognostics Announces Collaboration To Help Underserved Communities Make Informed Decisions About Prenatal Health PR Newswire
Oct-27-21 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter 2021 Financial Results on November 9 PR Newswire
Oct-15-21 10:59AM	We're Not Very Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate Simply Wall St.
Sep-28-21 08:30AM	Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer GlobeNewswire
Sep-20-21 08:30AM	Sera Prognostics to be Added to Russell 2000 Index GlobeNewswire
Sep-15-21 08:00AM	Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer GlobeNewswire -6.73%
Sep-14-21 08:00AM	Sera Prognostics Announces Publication of Health Economic Analysis Supporting PreTRM® Test-and-Treat Strategy to Improve Maternal and Infant Health GlobeNewswire
Sep-13-21 08:00AM	Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit GlobeNewswire
Aug-30-21 04:05PM	Sera Prognostics Reports Second Quarter 2021 Financial Results GlobeNewswire -6.60%
Aug-17-21 08:00AM	Sera Prognostics PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility GlobeNewswire
Jul-14-21 09:03PM	Sera Prognostics Announces Pricing of Initial Public Offering GlobeNewswire

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boniface John J.	Chief Scientific Officer	May 24	Sale	1.54	2,725	4,196	71,035	May 24 06:16 PM
Boniface John J.	Chief Scientific Officer	May 17	Sale	1.55	2,725	4,224	73,760	May 17 06:41 PM
Boniface John J.	Chief Scientific Officer	May 10	Sale	1.97	2,725	5,368	76,485	May 10 06:47 PM
Boniface John J.	Chief Scientific Officer	May 04	Option Exercise	0.73	1,000	730	80,210	May 04 06:15 PM
Boniface John J.	Chief Scientific Officer	May 04	Sale	2.17	1,000	2,170	79,210	May 04 06:15 PM
Boniface John J.	Chief Scientific Officer	May 03	Sale	2.17	2,725	5,913	79,210	May 03 05:43 PM
Boniface John J.	Chief Scientific Officer	Apr 26	Sale	2.17	2,725	5,913	81,935	Apr 26 06:28 PM
Boniface John J.	Chief Scientific Officer	Apr 19	Sale	2.08	2,725	5,668	84,660	Apr 20 04:36 PM
Boniface John J.	Chief Scientific Officer	Apr 12	Sale	2.66	2,725	7,248	87,385	Apr 13 04:26 PM
Boniface John J.	Chief Scientific Officer	Apr 06	Option Exercise	0.73	1,000	730	91,110	Apr 07 04:09 PM
Boniface John J.	Chief Scientific Officer	Apr 06	Sale	3.02	1,000	3,020	90,110	Apr 07 04:09 PM
Boniface John J.	Chief Scientific Officer	Apr 05	Sale	3.35	2,725	9,129	90,110	Apr 07 04:09 PM
Boniface John J.	Chief Scientific Officer	Mar 29	Sale	3.73	2,725	10,164	92,835	Mar 30 04:07 PM
Boniface John J.	Chief Scientific Officer	Mar 22	Sale	3.68	2,725	10,028	95,560	Mar 23 04:11 PM
Boniface John J.	Chief Scientific Officer	Mar 14	Sale	3.94	2,725	10,736	98,285	Mar 15 05:58 PM
Boniface John J.	Chief Scientific Officer	Mar 11	Option Exercise	0.73	75,998	55,479	101,010	Mar 14 04:16 PM
Boniface John J.	Chief Scientific Officer	Dec 06	Option Exercise	0.73	25,012	18,259	25,012	Dec 06 09:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience